T3D
MINT IT. PRINT IT.

9 June 2026

Strategic Investment in Firmus and Update on AI Product Development

- **$150,000 strategic investment in Firmus, a leading next-generation AI data centre platform**
- **Provides 333D with early, capital-efficient exposure to the rapidly expanding AI infrastructure sector**
- **AI clinical product development continues to advance through structured technical phases, complementing the Firmus exposure**
- **Investment funded from existing cash reserves; non-material with no change in the nature of the Company's activities**

The Board of Directors of 333D Ltd (ASX:T3D or "**Company**"), a company specialising in the creation and management of digital assets, is pleased to announce that it has secured a strategic foothold in the rapidly expanding AI infrastructure sector through a $150,000 investment in Firmus Grid Limited ACN 638 040 534 (**Firmus**), a next-generation AI data centre platform focused on high-performance compute infrastructure.

Strategic Investment in Firmus

Firmus is one of the most credentialled emerging companies in the Australian AI infrastructure landscape. The Company is backed by NVIDIA and recently completed a US$505 million capital raise led by Coatue Management, valuing the business at approximately US$5.5 billion. Firmus is constructing Project Southgate, a purpose-built AI factory campus in Launceston, Tasmania, supported by a US$10 billion debt facility arranged with Blackstone. Firmus has indicated it is targeting an ASX listing in 2026.

This investment provides 333D with early exposure to global demand for AI-driven data processing and digital infrastructure, complementing the Company's existing capabilities in digital asset management, AI-enabled data solutions, and software development.

Update on AI Product Development

In parallel with the Firmus investment, 333D has continued to progress its proprietary AI clinical-software development programs based on the DICOM digital assets. The development pathway is structured around a multi-phase technical and regulatory framework aligned with the Therapeutic Goods Administration's regulatory environment for software-based medical devices.

Over recent months, the development team has completed a major model training and evaluation milestone and is currently progressing through pre-deployment optimisation and validation activities. Training was conducted on a multi-thousand-study dataset of de-identified cone-beam CT (CBCT) scans sourced under a data-sharing arrangement with Next Healthcare (*see ASX announcement 31 July 2024*). Next Healthcare is a company controlled by 333D Chairman John Conidi, and as such, the data-sharing arrangement is governed at arm's length under the oversight of the Company's independent directors.

333D Limited
ABN 24 118 159 881
Level 23, Rialto South Tower,
525 Collins Street,
Melbourne VIC 3000 Australia

The software product is being developed for application in the dental and maxillofacial imaging market, with potential commercial pathways through both clinical-network integration and standalone software offerings. The Board will provide further substantive updates as the project reaches subsequent technical and commercial milestones.

Strategic Rationale

The Board views these two initiatives as complementary expressions of a single strategic direction. The Firmus investment provides 333D shareholders with direct minority exposure to Australian AI infrastructure at a credentialled pre-listing valuation, while the Company's in-house AI product development builds proprietary intellectual property and a regulated commercial pathway exploiting the Company's expertise in digital asset management. Together they position 333D at the intersection of applied AI and AI infrastructure — a structurally significant theme for global capital markets.

This is a targeted, capital-efficient entry point into a high-growth sector and is consistent with the Board's stated focus on disciplined capital allocation toward initiatives where 333D's existing capabilities and external sector exposure can be combined to create shareholder value.

Capital Position

The Firmus investment was funded from the Company's existing cash reserves and represents approximately 18.6% of cash reserves and 14.7% of total liquidity as at 31 March 2026. The Board considers the investment not to be material to the Company and does not constitute a change in the nature of the Company's activities. The Company retains sufficient liquidity to continue funding its existing operations, including ongoing AI product development.

- END -

The release of this announcement was **authorised by the Board of Directors** of the Company.

About 333D Limited

333D Limited is a company that seeks to capitalise upon opportunities in the digital line of business as new technologies are developed from both digital capture and digital creation perspectives, that will lend themselves for use in a myriad of interfaces, both physical (3D printed) and/or across other or additional digital platforms. 333D specialises in the digital capture of a subject matter; digital creation of data files incorporating diagnostic or medical imaging in DICOM format, 2D, 3D and animated digital content including still photography, digital design and motion video; and encoding data files using artificial intelligence such that a digitally created file is generated that is viewable in a 3D format and capable of being printed by a 3D printer. 333D Limited also provides bespoke design and management of digital assets (including 3D print files) and bespoke 3D printing bureau services

To find out more about 333D visit 333D.co

For further enquiries please contact:

John Conidi – Chief Executive Officer & Managing Director
+61 (0) 411 773 101
john@333d.co